Quan điểm của Cost-eﬀectiveness of brentuximab vedotin in treating increased risk of relapse/progression of classical hodgkin lymphoma patients post autologous stem cell transplant

Quay trở lại chi tiết bài viết Cost-eﬀectiveness of brentuximab vedotin in treating increased risk of relapse/progression of classical hodgkin lymphoma patients post autologous stem cell transplant Tải xuống tải PDF